📗 Cite This Artifact
Treatment Efficacy Rankings
Treatment Efficacy Rankings
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Treatment Efficacy Rankings</th>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Lecanemab](/therapeutics/lecanemab)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Donanemab](/therapeutics/donanemab)</td>
</tr>
<tr>
<td class="label">3</td>
<td>[Aducanumab](/therapeutics/aducanumab)</td>
</tr>
<tr>
<td class="label">4</td>
<td>[Atabecestat](/therapeutics/atabecestat)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Donepezil](/therapeutics/donepezil)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Memantine](/therapeutics/memantine)</td>
</tr>
<tr>
<td class="label">3</td>
<td>[Rivastigmine](/therapeutics/rivastigmine)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Levodopa/Carbidopa](/therapeutics/levodopa)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Deep Brain Stimulation](/therapeutics/deep-brain-stimulation)</td>
</tr>
<tr>
<td class="label">3</td>
<td>[ Pramipexole](/therapeutics/pramipexole)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Inosine](/therapeutics/inosine)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[GM1 ganglioside]
Treatment Efficacy Rankings
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Treatment Efficacy Rankings</th>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Lecanemab](/therapeutics/lecanemab)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Donanemab](/therapeutics/donanemab)</td>
</tr>
<tr>
<td class="label">3</td>
<td>[Aducanumab](/therapeutics/aducanumab)</td>
</tr>
<tr>
<td class="label">4</td>
<td>[Atabecestat](/therapeutics/atabecestat)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Donepezil](/therapeutics/donepezil)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Memantine](/therapeutics/memantine)</td>
</tr>
<tr>
<td class="label">3</td>
<td>[Rivastigmine](/therapeutics/rivastigmine)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Levodopa/Carbidopa](/therapeutics/levodopa)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Deep Brain Stimulation](/therapeutics/deep-brain-stimulation)</td>
</tr>
<tr>
<td class="label">3</td>
<td>[ Pramipexole](/therapeutics/pramipexole)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Inosine](/therapeutics/inosine)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[GM1 ganglioside](/therapeutics/gm1-ganglioside)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Tofersen](/therapeutics/tofersen)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Riluzole](/therapeutics/riluzole)</td>
</tr>
<tr>
<td class="label">3</td>
<td>[Edaravone](/therapeutics/edaravone)</td>
</tr>
<tr>
<td class="label">4</td>
<td>[Relyvrio](/therapeutics/relyvrio)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Tetrabenazine](/therapeutics/tetrabenazine)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Deutetrabenazine](/therapeutics/deutetrabenazine)</td>
</tr>
<tr>
<td class="label">3</td>
<td>[Tominersen](/therapeutics/tominersen)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Structured exercise (aerobic + resistance + balance)</td>
</tr>
<tr>
<td class="label">2</td>
<td>Mediterranean/MIND diet</td>
</tr>
<tr>
<td class="label">3</td>
<td>Multidisciplinary rehabilitation (PT/OT/SLP)</td>
</tr>
<tr>
<td class="label">4</td>
<td>Rasagiline (MAO-B inhibitor)</td>
</tr>
<tr>
<td class="label">5</td>
<td>Rapamycin (mTOR inhibition)</td>
</tr>
<tr>
<td class="label">6</td>
<td>TUDCA/UDCA (bile acid therapy)</td>
</tr>
<tr>
<td class="label">7</td>
<td>Vitamin D supplementation</td>
</tr>
<tr>
<td class="label">8</td>
<td>Spermidine (autophagy induction)</td>
</tr>
<tr>
<td class="label">9</td>
<td>Photobiomodulation (PBM)</td>
</tr>
<tr>
<td class="label">10</td>
<td>Cognitive reserve/mental engagement</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">11</td>
<td>Resveratrol/SIRT1 activation</td>
</tr>
<tr>
<td class="label">12</td>
<td>Creatine supplementation</td>
</tr>
<tr>
<td class="label">13</td>
<td>Methylene Blue/LMTX</td>
</tr>
<tr>
<td class="label">14</td>
<td>Coenzyme Q10</td>
</tr>
<tr>
<td class="label">15</td>
<td>Ambroxol (GCase chaperone)</td>
</tr>
<tr>
<td class="label">16</td>
<td>Omega-3 fatty acids (DHA/EPA)</td>
</tr>
<tr>
<td class="label">17</td>
<td>Sleep optimization/apnea treatment</td>
</tr>
<tr>
<td class="label">18</td>
<td>NACET</td>
</tr>
<tr>
<td class="label">19</td>
<td>Sulforaphane/Nrf2 activation</td>
</tr>
<tr>
<td class="label">20</td>
<td>Deferiprone (iron chelation)</td>
</tr>
<tr>
<td class="label">Symptom</td>
<td>First-Line</td>
</tr>
<tr>
<td class="label">Motor/Bradykinesia</td>
<td>Levodopa (trial)</td>
</tr>
<tr>
<td class="label">Falls/Postural instability</td>
<td>Physical therapy</td>
</tr>
<tr>
<td class="label">Neck dystonia (retrocollis)</td>
<td>Botulinum toxin</td>
</tr>
<tr>
<td class="label">Depression</td>
<td>SSRIs</td>
</tr>
<tr>
<td class="label">Apathy</td>
<td>Methylphenidate</td>
</tr>
<tr>
<td class="label">Pseudobulbar affect</td>
<td>Dextromethorphan/quinidine</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Structured exercise (aerobic + resistance + balance)</td>
</tr>
<tr>
<td class="label">2</td>
<td>Mediterranean/MIND diet</td>
</tr>
<tr>
<td class="label">3</td>
<td>Multidisciplinary rehabilitation (PT/OT/SLP)</td>
</tr>
<tr>
<td class="label">4</td>
<td>Rasagiline (MAO-B inhibitor)</td>
</tr>
<tr>
<td class="label">5</td>
<td>Rapamycin (mTOR inhibition)</td>
</tr>
<tr>
<td class="label">6</td>
<td>TUDCA/UDCA (bile acid therapy)</td>
</tr>
<tr>
<td class="label">7</td>
<td>Vitamin D supplementation</td>
</tr>
<tr>
<td class="label">8</td>
<td>Spermidine (autophagy induction)</td>
</tr>
<tr>
<td class="label">9</td>
<td>Photobiomodulation (PBM)</td>
</tr>
<tr>
<td class="label">10</td>
<td>Cognitive reserve/mental engagement</td>
</tr>
<tr>
<td class="label">Symptom</td>
<td>First-Line</td>
</tr>
<tr>
<td class="label">Motor symptoms</td>
<td>Levodopa trial</td>
</tr>
<tr>
<td class="label">Dystonia</td>
<td>Botulinum toxin</td>
</tr>
<tr>
<td class="label">Myoclonus</td>
<td>Levetiracetam, clonazepam</td>
</tr>
<tr>
<td class="label">Cognitive impairment</td>
<td>Donepezil, rivastigmine</td>
</tr>
<tr>
<td class="label">Apathy</td>
<td>Methylphenidate</td>
</tr>
<tr>
<td class="label">Depression/Anxiety</td>
<td>SSRIs</td>
</tr>
<tr>
<td class="label">Treatment</td>
<td>Efficacy</td>
</tr>
<tr>
<td class="label">[Donepezil](/entities/donepezil)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Rivastigmine](/entities/rivastigmine)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Memantine</td>
<td>Modest</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Treatment</td>
<td>Efficacy</td>
</tr>
<tr>
<td class="label">Carbidopa/levodopa</td>
<td>High</td>
</tr>
<tr>
<td class="label">Dopamine agonists</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">MAO-B inhibitors</td>
<td>Modest</td>
</tr>
<tr>
<td class="label">Deep brain stimulation</td>
<td>High</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>Disease</td>
</tr>
<tr>
<td class="label">High</td>
<td>Parkinson's</td>
</tr>
<tr>
<td class="label">High</td>
<td>Parkinson's</td>
</tr>
<tr>
<td class="label">High</td>
<td>Parkinson's</td>
</tr>
<tr>
<td class="label">High</td>
<td>Parkinson's</td>
</tr>
<tr>
<td class="label">High</td>
<td>FTD</td>
</tr>
<tr>
<td class="label">High</td>
<td>CBS</td>
</tr>
<tr>
<td class="label">High</td>
<td>PSP</td>
</tr>
<tr>
<td class="label">Treatment</td>
<td>Current Words</td>
</tr>
<tr>
<td class="label">Ropinirole</td>
<td>6289</td>
</tr>
<tr>
<td class="label">Rotigotine</td>
<td>6620</td>
</tr>
<tr>
<td class="label">Entacapone</td>
<td>6231</td>
</tr>
</table>
Treatment Efficacy Rankings is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research. [@neurowiki]
Rankings of treatments by clinical efficacy, disease modification evidence, safety profile, and clinical utility across neurodegenerative diseases.
Alzheimer's Disease Treatments
Disease-Modifying Therapies (DMTs)
Symptomatic Therapies
Parkinson's Disease Treatments
Motor Symptoms
Disease-Modifying Candidates
ALS Treatments
Huntington's Disease
Progressive Supranuclear Palsy (PSP) Treatments
PSP is a 4R-tauopathy with no FDA-approved disease-modifying therapies. Treatment focuses on symptomatic management, neuroprotection, and rehabilitation. See the [PSP Treatment](/therapeutics/progressive-supranuclear-psp-psp-treatment) page for detailed protocols and the [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings) for evidence-scored interventions.
Tier 1: Strong Evidence Interventions
Tier 2: Moderate Evidence
Key Symptomatic Treatments
Emerging Disease-Modifying Approaches
- Tideglusib (GSK-3β inhibitor): Phase 2 completed[^39]
- Rapamycin: mTOR inhibition for autophagy
- ApoE-targeted therapies: Genetic subset considerations
Corticobasal Syndrome (CBS) Treatments
CBS presents unique challenges due to heterogeneous pathology. Like PSP, no disease-modifying therapies exist. Treatment is symptomatic and rehabilitative. See the [CBS Treatment](/therapeutics/corticobasal-cbs-treatment) page for detailed protocols.
Tier 1: Strong Evidence Interventions
Key Symptomatic Treatments
Disease-Modifying Pipeline
- Tau immunotherapies: Gantenerumab, semorinemab (failed in CBS)
- Tideglusib: GSK-3β inhibitor (Phase 2)[^39]
- Lithium: Low-dose (Phase 2)[^30]
Efficacy Metrics
Clinical Outcome Measures
- ADAS-Cog: Alzheimer's cognition (0-70)
- MDS-UPDRS: Parkinson's motor (0-132)
- ALSFRS-R: ALS function (0-48)
- UHDRS: Huntington's (0-400)
Biomarker Correlates
- Amyloid PET SUVr reduction
- CSF p-[tau](/proteins/tau)/t-tau ratio
- Volumetric MRI loss rate
Safety Rankings
Best Tolerability
Notable Safety Concerns
- ARIA (brain edema/hemorrhage): Aducanumab, [Lecanemab](/entities/lecanemab), [Donanemab](/entities/donanemab)
- Liver toxicity: Many Phase 1 compounds
- Cardiac: Some dopamine agonists
Symptomatic Treatment Rankings
Cognitive Symptoms
Motor Symptoms (PD)
Disease-Modifying Therapy Rankings
By Mechanism Validation
By Development Progress
- Advanced (Phase 3+): Lecanemab, Donanemab, Inosine
- Mid-stage (Phase 2): TREM2 agonists, gene therapies
- Early (Phase 1): Novel small molecules, cell therapies
Related Pages
- [Treatment Pipeline Overview](/treatment-pipeline-overview)
- [Drug Target Landscape](/drug-target-landscape)
- [Protein Drug Targets](/proteins/protein-drug-targets)
- [Therapeutic Targetability](/mechanisms/_therapeutic-targets)
Coverage Gaps and Needs Work
This section identifies missing or underdeveloped treatment pages that need coverage.
Critical Treatment Gaps
The following treatments have no dedicated pages but are important for neurodegenerative disease management:
Underdeveloped Existing Pages
Some treatment pages exist but need expansion:
Task Recommendations
Based on this analysis, the following tasks should be created:
See Also
- [Lecanemab](/clinical-trials/lecanemab-clarity-ad)
- [Donanemab](/clinical-trials/nct05738486)
- [Aducanumab](/therapeutics/aducanumab)
- [Atabecestat](/mechanisms/dopaminergic-neuron-vulnerability)
- [Donepezil](/entities/donepezil)
- [Memantine](/therapeutics/memantine)
- [Rivastigmine](/entities/rivastigmine)
- [Levodopa/Carbidopa](/therapeutics/carbidopa)
- [Deep Brain Stimulation](/technologies/deep-brain-stimulation)
- [Pramipexole](/clinical-trials/pramipexole-early-pd)
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | therapeutics-treatment-rankings |
| kg_node_id | None |
| entity_type | therapeutic |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-7480a07d6d14 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-treatment-rankings'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-therapeutics-treatment-rankings?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Treatment Efficacy Rankings](http://scidex.ai/artifact/wiki-therapeutics-treatment-rankings)
http://scidex.ai/artifact/wiki-therapeutics-treatment-rankings